SCHEMBL20135164

SCHEMBL20135164

Cc1cc(C(=O)O)ccc1C(=O)C(C)C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM1 Q13255 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
MEN1 O00255 1/20 0.50
CYP1A2 P05177 1/20 0.50
KMT2A Q03164 1/20 0.50
ACE2 Q9BYF1 2/20 0.47
TSHR P16473 3/20 0.47
MYC P01106 2/20 0.47
ESR1 P03372 1/20 0.47
ALOX15 P16050 1/20 0.47
PTPN7 P35236 1/20 0.47
HSD17B10 Q99714 1/20 0.47
KDM4E B2RXH2 2/20 0.44
DBH P09172 1/20 0.44
GAA P10253 1/20 0.44
RECQL P46063 1/20 0.44
ALDH1A1 P00352 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
EPHX2 P34913 1/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12377747 0.85 ACE2 (0.51) TDP1KMT2AACE2TSHRMYC
SCHEMBL5432556 0.81 LMNA (0.50) ACE2MYCKDM4EDBHGAA
SCHEMBL29399874 0.81 MYC (0.58) GRM1TDP1MEN1CYP1A2KMT2A
SCHEMBL44342 0.81 MYC (0.58) GRM1TDP1MEN1CYP1A2KMT2A
SCHEMBL20135009 0.80 KDM4E (0.56) TDP1MEN1KMT2AALOX15HSD17B10
SCHEMBL5716706 0.80 TAS1R3 (0.46) TDP1MEN1KMT2AKDM4EDBH
Water SCHEMBL3832510 0.79 MYC (0.56) GRM1TDP1MEN1CYP1A2KMT2A
Hydrochloric Acid SCHEMBL3169435 0.79 MYC (0.56) GRM1TDP1MEN1CYP1A2KMT2A
SCHEMBL11454527 0.79 MYC (0.61) GRM1TDP1MEN1CYP1A2KMT2A
Ammonia Solution, Strong SCHEMBL11880552 0.79 MYC (0.56) GRM1TDP1MEN1CYP1A2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 GRM1 4141/4885TDP1 2301/4885MEN1 3735/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 GRM1 3929/4885TDP1 2384/4885MEN1 2913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.